We are developing high concentrated EPA health products specifically adapted and dedicated to patients experiencing health conditions and diseases that would beneficiate of EPA support.
The greater impacts of the products developed through the project will be for patients; they could have their treatments (as cancer chemo/radiotherapy treatments and surgeries) outcomes improved, their length of hospital stay reduced, and their quality of life during and after treatment increased. As the number of patients in EU and US that are under cancer chemo/radiotherapy treatments or have surgeries is very high, the number of patients that can see the health conditions increased by Solutex product is major.
Solutex products would also impact the government and private investments in health. By optimizing treatments and reducing length of hospital stay, the cost for treating cancer and surgery patients could be decreased.
The impact will also be great in the company’s benefit, which will achieve more than 15 million € of benefits during the first three years of commercialization. More than 14 new people will be directly recruited in the project during the firsts three years of commercialization. Also, the indirect employment, especially in sales force, will reach up to almost 600 people.
The supercritical CO2 extraction technology is eco-innovative as it provides an environmentally benign alternative to solvent chromatography since there are no residues related to concentration, either residual water, liquid solvents or steams. Solutex material used in its products is processed through the cleanest technology, without emitting any contaminants to the atmosphere. Thus, Solutex products will also positively impact the environment by being less damageable than the existing equivalent technologies.
